{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:59:10Z","timestamp":1774285150449,"version":"3.50.1"},"posted":{"date-parts":[[2025,11,5]]},"group-title":"In Review","reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,10]]},"abstract":"<title>Abstract<\/title>\n                <p>There is a growing interest in the role of sphingolipids in the background of multiple sclerosis (MS). The goal of this study was to evaluate the serum levels of antibodies against ceramide-1-phosphate (C1P) subclasses and their relationships with clinical status in MS.The study groups comprised 39 patients with relapsing-remitting MS (RRMS), 26 patients with other neurological diseases (OND) and 12 healthy subjects (HS). Anti-C1P IgG levels in serum were determined using ELISA test. Levels of anti-C18:0-C1P and anti-C24:1-C1P IgG were significantly increased (p\u2009=\u20090.0005; p\u2009&lt;\u20090.0001, respectively) in RRMS compared to HS, while anti-C16:0-C1P and anti-C24:0-C1P IgG \u2013 significantly lower (p\u2009&lt;\u20090.0001) in RRMS compared to OND. Validation by ROC and cluster analysis confirmed the ability of these anti-C1P IgG panels to discriminate between the study groups. In addition, level of anti-C24:1-C1P IgG was significantly lower (p\u2009=\u20090.0448) in RRMS patients with relapse than in those with remission. No relationships were found between levels of antibodies in the anti-C1P IgG panel in RRMS group and disease duration, degree of disability or Link index.These findings highlight the relevant role of C1P as a target and\/or mediator of autoimmune response in MS and potential value of anti-C1P antibodies as biomarkers in differential diagnosis of this disease.<\/p>","DOI":"10.21203\/rs.3.rs-7825469\/v1","type":"posted-content","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:51:09Z","timestamp":1762329069000},"source":"Crossref","is-referenced-by-count":0,"title":["Presence and relevance of serum anti-C1P IgG antibodies in relapsing-remitting multiple sclerosis"],"prefix":"10.21203","author":[{"given":"Justyna","family":"Chojdak-Lukasiewicz","sequence":"first","affiliation":[{"name":"Wroclaw Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jakubiak-Augustyn","sequence":"additional","affiliation":[{"name":"University of Wroclaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdzislaw M.","family":"Szulc","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Gubernator","sequence":"additional","affiliation":[{"name":"University of Wroclaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pokryszko-Dragan","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomir","family":"Budrewicz","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Podbielska","sequence":"additional","affiliation":[{"name":"Ludwik Hirszfeld Institute of Immunology and Experimental Therapy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson R","year":"2019","unstructured":"Dobson, R. & Giovannoni, G. Multiple sclerosis - a review. Eur. J. Neurol. 26, 27\u201340. 10.1111\/ene.13819 (2019).","journal-title":"Eur. J. Neurol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis","volume":"9","author":"Lassmann H","year":"2018","unstructured":"Lassmann, H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front. Immunol. 9, 3116. 10.3389\/fimmu.2018.03116 (2018).","journal-title":"Front. Immunol."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15091178","article-title":"Neurodegenerative Biomarkers in Multiple Sclerosis: At the Interface Between Research and Clinical Practice","volume":"15","author":"Ciubotaru A","year":"2025","unstructured":"Ciubotaru, A. et al. Neurodegenerative Biomarkers in Multiple Sclerosis: At the Interface Between Research and Clinical Practice. Diagnostics (Basel). 15 10.3390\/diagnostics15091178 (2025).","journal-title":"Diagnostics (Basel)"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/metabo14100545","article-title":"Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis","volume":"14","author":"Pousinis P","year":"2024","unstructured":"Pousinis, P. et al. Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis. Metabolites 14, 545 (2024).","journal-title":"Metabolites"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189207","article-title":"Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives-A Systematic Review","volume":"26","author":"Smusz J","year":"2025","unstructured":"Smusz, J. et al. Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives-A Systematic Review. Int. J. Mol. Sci. 26 10.3390\/ijms26189207 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052483","article-title":"Plasma Lipidomic Profiling Using Mass Spectrometry for Multiple Sclerosis Diagnosis and Disease Activity Stratification (LipidMS)","volume":"25","author":"Lattau SSJ","year":"2024","unstructured":"Lattau, S. S. J. et al. Plasma Lipidomic Profiling Using Mass Spectrometry for Multiple Sclerosis Diagnosis and Disease Activity Stratification (LipidMS). Int. J. Mol. Sci. 25 10.3390\/ijms25052483 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"15644","DOI":"10.1038\/s41598-020-72654-8","article-title":"Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration","volume":"10","author":"Amatruda M","year":"2020","unstructured":"Amatruda, M. et al. Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration. Sci. Rep. 10, 15644. 10.1038\/s41598-020-72654-8 (2020).","journal-title":"Sci. Rep."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ncl.2023.06.008","article-title":"Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis","volume":"42","author":"Chertcoff A","year":"2024","unstructured":"Chertcoff, A., Schneider, R., Azevedo, C. J., Sicotte, N. & Oh, J. Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis. Neurol. Clin. 42, 15\u201338. 10.1016\/j.ncl.2023.06.008 (2024).","journal-title":"Neurol. Clin."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147319","article-title":"New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration","volume":"22","author":"Podbielska M","year":"2021","unstructured":"Podbielska, M., O'Keeffe, J. & Pokryszko-Dragan, A. New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration. Int. J. Mol. Sci. 22 10.3390\/ijms22147319 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1093\/brain\/awu139","article-title":"Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics","volume":"137","author":"Vidaurre OG","year":"2014","unstructured":"Vidaurre, O. G. et al. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 137, 2271\u20132286. 10.1093\/brain\/awu139 (2014).","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/1352458514561908","article-title":"Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis","volume":"21","author":"Checa A","year":"2015","unstructured":"Checa, A. et al. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Mult Scler. 21, 1271\u20131279. 10.1177\/1352458514561908 (2015).","journal-title":"Mult Scler."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1177\/1352458520971816","article-title":"Serum ceramide levels are altered in multiple sclerosis","volume":"27","author":"Filippatou AG","year":"2021","unstructured":"Filippatou, A. G. et al. Serum ceramide levels are altered in multiple sclerosis. Mult Scler. 27, 1506\u20131519. 10.1177\/1352458520971816 (2021).","journal-title":"Mult Scler."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1042\/CS20180506","article-title":"The relevance of ceramides and their synthesizing enzymes for multiple sclerosis","volume":"132","author":"Kurz J","year":"2018","unstructured":"Kurz, J. et al. The relevance of ceramides and their synthesizing enzymes for multiple sclerosis. Clin. Sci. (Lond). 132, 1963\u20131976. 10.1042\/CS20180506 (2018).","journal-title":"Clin. Sci. (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1194\/jlr.M070664","article-title":"Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line","volume":"57","author":"Podbielska M","year":"2016","unstructured":"Podbielska, M. et al. Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J. Lipid Res. 57, 2028\u20132039. 10.1194\/jlr.M070664 (2016).","journal-title":"J. Lipid Res."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1194\/jlr.RA120001022","article-title":"Distinctive sphingolipid patterns in chronic multiple sclerosis lesions","volume":"61","author":"Podbielska M","year":"2020","unstructured":"Podbielska, M. et al. Distinctive sphingolipid patterns in chronic multiple sclerosis lesions. J. Lipid Res. 61, 1464\u20131479. 10.1194\/jlr.RA120001022 (2020).","journal-title":"J. Lipid Res."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"104565","DOI":"10.1016\/j.msard.2023.104565","article-title":"Ceramide is implicated in humoral peripheral and intrathecal autoimmune response in MS patients","volume":"71","author":"Podbielska M","year":"2023","unstructured":"Podbielska, M. et al. Ceramide is implicated in humoral peripheral and intrathecal autoimmune response in MS patients. Mult Scler. Relat. Disord. 71, 104565. 10.1016\/j.msard.2023.104565 (2023).","journal-title":"Mult Scler. Relat. Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","author":"Thompson AJ","year":"2017","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 10.1016\/S1474-4422(17)30470-2 (2017).","journal-title":"Lancet Neurol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"7821","DOI":"10.1016\/S0040-4039(00)01361-7","article-title":"A facile regioselective synthesis of sphingosine 1-phosphate and ceramide 1-phosphate","volume":"41","author":"Szulc ZM","year":"2000","unstructured":"Szulc, Z. M., Hannun, Y. A. & Bielawska, A. A facile regioselective synthesis of sphingosine 1-phosphate and ceramide 1-phosphate. Tetrahedron Lett. 41, 7821\u20137824. 10.1016\/S0040-4039(00)01361-7 (2000).","journal-title":"Tetrahedron Lett."},{"key":"ref19","author":"Rappoport A","year":"2025","unstructured":"Rappoport, A. in The Science of the Brain (ed Ari Rappoport) 161\u2013176Academic Press, (2025)."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/1352458509106708","article-title":"Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?","volume":"15","author":"Podbielska M","year":"2009","unstructured":"Podbielska, M. & Hogan, E. L. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult Scler. 15, 1011\u20131029. 10.1177\/1352458509106708 (2009).","journal-title":"Mult Scler."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1750-3639.2011.00501.x","article-title":"Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury","volume":"22","author":"Kim S","year":"2012","unstructured":"Kim, S., Steelman, A. J., Zhang, Y., Kinney, H. C. & Li, J. Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol. 22, 41\u201357. 10.1111\/j.1750-3639.2011.00501.x (2012).","journal-title":"Brain Pathol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000484621","article-title":"Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase\/Ceramide System","volume":"25","author":"Becker KA","year":"2017","unstructured":"Becker, K. A. et al. Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase\/Ceramide System. Neuro-Signals 25, 88\u201397. 10.1159\/000484621 (2017).","journal-title":"Neuro-Signals"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/nu15010229","article-title":"Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment","volume":"15","author":"Alexandropoulou I","year":"2023","unstructured":"Alexandropoulou, I. et al. Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment. Nutrients 15 10.3390\/nu15010229 (2023).","journal-title":"Nutrients"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158082","article-title":"Ceramide\/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases","volume":"23","author":"Custodia A","year":"2022","unstructured":"Custodia, A. et al. Ceramide\/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases. Int. J. Mol. Sci. 23 10.3390\/ijms23158082 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf093","article-title":"Ceramides in cardiovascular disease - emerging role as independent risk predictors and novel therapeutic targets","author":"Klingenberg R","year":"2025","unstructured":"Klingenberg, R. et al. Ceramides in cardiovascular disease - emerging role as independent risk predictors and novel therapeutic targets. Cardiovascular. Res. 10.1093\/cvr\/cvaf093 (2025).","journal-title":"Cardiovascular. Res."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"109980","DOI":"10.1016\/j.cellsig.2021.109980","article-title":"Regulation of cell growth, survival and migration by ceramide 1-phosphate - implications in lung cancer progression and inflammation","volume":"83","author":"Gomez-Larrauri A","year":"2021","unstructured":"Gomez-Larrauri, A., Ouro, A., Trueba, M. & Gomez-Munoz, A. Regulation of cell growth, survival and migration by ceramide 1-phosphate - implications in lung cancer progression and inflammation. Cell. Signal. 83, 109980. 10.1016\/j.cellsig.2021.109980 (2021).","journal-title":"Cell. Signal."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bcp.2005.12.027","article-title":"Ceramide-1-phosphate activates cytosolic phospholipase A2alpha directly and by PKC pathway","volume":"71","author":"Nakamura H","year":"2006","unstructured":"Nakamura, H., Hirabayashi, T., Shimizu, M. & Murayama, T. Ceramide-1-phosphate activates cytosolic phospholipase A2alpha directly and by PKC pathway. Biochem. Pharmacol. 71, 850\u2013857. 10.1016\/j.bcp.2005.12.027 (2006).","journal-title":"Biochem. Pharmacol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2796.2008.02035.x","article-title":"Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis","volume":"265","author":"Mattsson N","year":"2009","unstructured":"Mattsson, N. et al. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J. Intern. Med. 265, 459\u2013464. 10.1111\/j.1365-2796.2008.02035.x (2009).","journal-title":"J. Intern. Med."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0022-510X(84)90085-6","article-title":"Regulation of lymphocyte activation by PGE2 in multiple sclerosis","volume":"65","author":"DuBois JH","year":"1984","unstructured":"DuBois, J. H. & Cuzner, M. L. Regulation of lymphocyte activation by PGE2 in multiple sclerosis. J. Neurol. Sci. 65, 211\u2013219. 10.1016\/0022-510X(84)90085-6 (1984).","journal-title":"J. Neurol. Sci."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00401-025-02878-3","article-title":"Spatial mapping of the AA-PGE2-EP axis in multiple sclerosis lesions","volume":"149","author":"Hansen CE","year":"2025","unstructured":"Hansen, C. E. et al. Spatial mapping of the AA-PGE2-EP axis in multiple sclerosis lesions. Acta Neuropathol. 149, 39. 10.1007\/s00401-025-02878-3 (2025).","journal-title":"Acta Neuropathol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/wnl.36.12.1587","article-title":"Prostaglandin release in multiple sclerosis: correlation with disease activity","volume":"36","author":"Dore-Duffy P","year":"1986","unstructured":"Dore-Duffy, P., Donaldson, J. O., Koff, T., Longo, M. & Perry, W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 36, 1587\u20131590. 10.1212\/wnl.36.12.1587 (1986).","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2174\/1871527319666200825164123","article-title":"A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis","volume":"21","author":"Hoxha M","year":"2022","unstructured":"Hoxha, M., Spahiu, E., Prendi, E. & Zappacosta, B. A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis. CNS Neurol. Disord. Drug Target. 21, 160\u2013187. 10.2174\/1871527319666200825164123 (2022).","journal-title":"CNS Neurol. Disord. Drug Target"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"17570","DOI":"10.1074\/jbc.M312885200","article-title":"Ceramide kinase is a mediator of calcium-dependent degranulation in mast cells","volume":"279","author":"Mitsutake S","year":"2004","unstructured":"Mitsutake, S. et al. Ceramide kinase is a mediator of calcium-dependent degranulation in mast cells. J. Biol. Chem. 279, 17570\u201317577. 10.1074\/jbc.M312885200 (2004).","journal-title":"J. Biol. Chem."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.4049\/jimmunol.1402681","article-title":"C1P Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Preventing NF-kappaB Activation in Neutrophils","volume":"196","author":"Baudiss K","year":"2016","unstructured":"Baudiss, K. et al. C1P Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Preventing NF-kappaB Activation in Neutrophils. J. Immunol. 196, 2319\u20132326. 10.4049\/jimmunol.1402681 (2016).","journal-title":"J. Immunol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"E1213","DOI":"10.1152\/ajpendo.00480.2012","article-title":"Ceramide 1-phosphate induces macrophage chemoattractant protein-1 release: involvement in ceramide 1-phosphate-stimulated cell migration","volume":"304","author":"Arana L","year":"2013","unstructured":"Arana, L. et al. Ceramide 1-phosphate induces macrophage chemoattractant protein-1 release: involvement in ceramide 1-phosphate-stimulated cell migration. Am. J. Physiol. Endocrinol. Metab. 304, E1213\u20131226. 10.1152\/ajpendo.00480.2012 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1124\/mol.116.107169","article-title":"Ceramide 1-Phosphate Increases P-Glycoprotein Transport Activity at the Blood-Brain Barrier via Prostaglandin E2 Signaling","volume":"91","author":"Mesev EV","year":"2017","unstructured":"Mesev, E. V., Miller, D. S. & Cannon, R. E. Ceramide 1-Phosphate Increases P-Glycoprotein Transport Activity at the Blood-Brain Barrier via Prostaglandin E2 Signaling. Mol. Pharmacol. 91, 373\u2013382. 10.1124\/mol.116.107169 (2017).","journal-title":"Mol. Pharmacol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbalip.2009.01.023","article-title":"Ceramide 1-phosphate inhibits serine palmitoyltransferase and blocks apoptosis in alveolar macrophages","volume":"1791","author":"Granado MH","year":"2009","unstructured":"Granado, M. H., Gangoiti, P., Ouro, A., Arana, L. & Gomez-Munoz, A. Ceramide 1-phosphate inhibits serine palmitoyltransferase and blocks apoptosis in alveolar macrophages. Biochim. Biophys. Acta. 1791, 263\u2013272. 10.1016\/j.bbalip.2009.01.023 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1194\/jlr.M300158-JLR200","article-title":"Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages","volume":"45","author":"Gomez-Munoz A","year":"2004","unstructured":"Gomez-Munoz, A., Kong, J. Y., Salh, B. & Steinbrecher, U. P. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J. Lipid Res. 45, 99\u2013105. 10.1194\/jlr.M300158-JLR200 (2004).","journal-title":"J. Lipid Res."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"8259","DOI":"10.1038\/s41598-021-87795-7","article-title":"Ceramide kinase regulates TNF-\u03b1-induced immune responses in human monocytic cells","volume":"11","author":"Al-Rashed F","year":"2021","unstructured":"Al-Rashed, F. et al. Ceramide kinase regulates TNF-\u03b1-induced immune responses in human monocytic cells. Sci. Rep-Uk. 11, 8259. 10.1038\/s41598-021-87795-7 (2021).","journal-title":"Sci. Rep-Uk"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbamem.2005.02.014","article-title":"Molecular associations and surface-active properties of short- and long-N-acyl chain ceramides","volume":"1711","author":"Sot J","year":"2005","unstructured":"Sot, J., Goni, F. M. & Alonso, A. Molecular associations and surface-active properties of short- and long-N-acyl chain ceramides. Biochim. Biophys. Acta. 1711, 12\u201319. 10.1016\/j.bbamem.2005.02.014 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"159092","DOI":"10.1016\/j.bbalip.2021.159092","article-title":"Species-specific accumulation of ceramides in cerebrospinal fluid from encephalomyeloradiculoneurpathy patients associated with peripheral complement activation: A pilot study","volume":"1867","author":"Mutoh T","year":"2022","unstructured":"Mutoh, T. et al. Species-specific accumulation of ceramides in cerebrospinal fluid from encephalomyeloradiculoneurpathy patients associated with peripheral complement activation: A pilot study. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids. 1867, 159092. 10.1016\/j.bbalip.2021.159092 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s11064-012-0728-y","article-title":"Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis","volume":"37","author":"Podbielska M","year":"2012","unstructured":"Podbielska, M., Krotkiewski, H. & Hogan, E. L. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. Neurochem Res. 37, 1154\u20131169. 10.1007\/s11064-012-0728-y (2012).","journal-title":"Neurochem Res."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1194\/jlr.D008532","article-title":"Blood sphingolipidomics in healthy humans: impact of sample collection methodology","volume":"51","author":"Hammad SM","year":"2010","unstructured":"Hammad, S. M. et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J. Lipid Res. 51, 3074\u20133087. 10.1194\/jlr.D008532 (2010).","journal-title":"J. Lipid Res."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3855\/jidc.513","article-title":"Anti-ceramide antibodies in leprosy: marker for nerve damage?","volume":"4","author":"Singh K","year":"2010","unstructured":"Singh, K., Singh, B. & Ray, P. Anti-ceramide antibodies in leprosy: marker for nerve damage? J. Infect. Dev. Ctries. 4, 378\u2013381 (2010).","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3389\/fimmu.2017.01386","article-title":"Critical Role for Very-Long Chain Sphingolipids in Invariant Natural Killer T Cell Development and Homeostasis","volume":"8","author":"Saroha A","year":"2017","unstructured":"Saroha, A. et al. Critical Role for Very-Long Chain Sphingolipids in Invariant Natural Killer T Cell Development and Homeostasis. Front. Immunol. 8, 1386. 10.3389\/fimmu.2017.01386 (2017).","journal-title":"Front. Immunol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1611929","DOI":"10.3389\/pore.2024.1611929","article-title":"Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer","volume":"30","author":"Budi L","year":"2024","unstructured":"Budi, L. et al. Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer. Pathol. Oncol. Res. 30, 1611929. 10.3389\/pore.2024.1611929 (2024).","journal-title":"Pathol. Oncol. Res."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e0186842","DOI":"10.1371\/journal.pone.0186842","article-title":"The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution","volume":"12","author":"Beseler C","year":"2017","unstructured":"Beseler, C., Vollmer, T., Graner, M. & Yu, X. The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution. PloS one. 12, e0186842. 10.1371\/journal.pone.0186842 (2017).","journal-title":"PloS one"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7825469\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7825469\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:06:09Z","timestamp":1774281969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7825469\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":47,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7825469\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41598-026-43823-y","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,11,5]]},"subtype":"preprint"}}